Prolactinomas account for approximately 50% of all pituitary adenomas coming to medical
attention and are an important cause of hypogonadism and infertility. The ultimate goal of …

The discovery and widespread use of dopamine agonists as an effective therapy for patients
with prolactinomas was a key therapeutic advance. However, despite the overall efficacy of …

Abstract Treatment of invasive prolactinoma, which has several characteristics including
invasive growth into cavernous sinuses and formation of giant adenomas compressing …

Introduction: Prolactinomas are unique tumors that may go into both hormonal and
radiographic remission with dopamine agonist therapy or transsphenoidal surgery …

Background Resistance to dopamine agonists is not uncommonly seen in prolactinomas.
However, development of resistance to dopamine agonists after an initial period of robust …

Prolactinoma is the most frequent pituitary adenoma type, accounting for 40–66% in
epidemiological studies [1]. The estimated prevalence in various populations ranges from …

Prolactinoma has the highest incidence rate among patients with functional pituitary
tumours. Although mostly benign, there is a subgroup that can be aggressive. Some clinical …

Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists
(DAs) are troublesome, and surgery often only removes a large part of the tumor without …

Prolactinomas, the most prevalent type of neuroendocrine disease, account for
approximately 40% of all pituitary adenomas. The most important clinical problems …

Objective: To describe outcomes of patients with giant prolactinoma (≥ 4 cm) and identify
predictors of therapeutic response. Methods: In this retrospective study, complete …